Regardless, SHOC2’s contribution to tumorigenic properties in some RAS-mutant human cells lines, as well as to tumor development in a KRAS-driven mouse LUAD model suggests targeting SHOC2 in the clinic may have activity as monotherapy against a subset of RAS-mutant cancers. The gene discussed is SHOC2; the disease is cancer.